Drug Type Small molecule drug |
Synonyms Deudomperidone, deuterated domperidone (CinRx Pharma), Domperidone (JP17/USAN/INN) + [6] |
Target |
Mechanism D2 receptor antagonists(Dopamine D2 receptor antagonists) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization- |
Active Organization |
Inactive Organization |
Drug Highest PhaseApproved |
First Approval Date JP (15 Jun 1982), |
Regulation- |
Molecular FormulaC22H24ClN5O2 |
InChIKeyFGXWKSZFVQUSTL-UHFFFAOYSA-N |
CAS Registry57808-66-9 |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Gastrointestinal Diseases | JP | 01 Sep 1982 | |
Nausea | JP | 01 Sep 1982 | |
Vomiting | JP | 01 Sep 1982 | |
Chronic gastritis | JP | 15 Jun 1982 | |
Diarrhea, Infantile | JP | 15 Jun 1982 | |
Gastroptosis | JP | 15 Jun 1982 | |
Heartburn | JP | 15 Jun 1982 | |
Nausea and vomiting | JP | 15 Jun 1982 | |
Postgastrectomy Syndromes | JP | 15 Jun 1982 | |
Respiratory Tract Infections | JP | 15 Jun 1982 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Gastroenteritis | Phase 3 | AT | 07 Dec 2015 | |
Gastroenteritis | Phase 3 | BE | 07 Dec 2015 | |
Gastroenteritis | Phase 3 | RU | 07 Dec 2015 | |
Gastroenteritis | Phase 3 | ZA | 07 Dec 2015 | |
Gastroenteritis | Phase 3 | ES | 07 Dec 2015 | |
Gastroenteritis | Phase 3 | GB | 07 Dec 2015 | |
Norovirus Infections | Phase 3 | AT | 07 Dec 2015 | |
Norovirus Infections | Phase 3 | BE | 07 Dec 2015 | |
Norovirus Infections | Phase 3 | RU | 07 Dec 2015 | |
Norovirus Infections | Phase 3 | ZA | 07 Dec 2015 |
Not Applicable | - | 184,929 | onlawfsswz(sevukrftjr) = aqcquzjpsq ndympjyswl (iwbxpgwbpj ) | - | 01 Apr 2021 | ||
Not Applicable | - | - | fmscsssyyp(cpzwuaixdl) = glhkkviawl hvhmbopzxd (jpsgxsmhge ) View more | - | 01 Mar 2021 | ||
Placebo | fmscsssyyp(cpzwuaixdl) = khxyhciydc hvhmbopzxd (jpsgxsmhge ) View more | ||||||
Not Applicable | - | 200 | mgxzexulgr(rkvkbwozwr) = tbxzorqqfw eaqxuejxkf (esrlolqatg, 44.8 - 117.5) View more | Negative | 01 Feb 2021 | ||
(Control) | mgxzexulgr(rkvkbwozwr) = xviqusoslf eaqxuejxkf (esrlolqatg, 42.0 - 128.0) View more | ||||||
Phase 2 | Multiple Sclerosis, Secondary Progressive prolactin levels | 110 | chbzszwuel(zgpeicaenf) = xkbegnwxds yqljhbexbi (zcdujkqwka ) | Negative | 11 May 2020 | ||
Phase 2 | 15 | aucphwtjax(outibeqyqu) = vtswehbzfc dgypfjmvzt (zbahnbdicm, 5.2) | - | 09 Oct 2018 | |||
Phase 2 | 44 | ccdyeiiwmi(hnfzchbgty) = nkfbninfnd lbjtjzzmtu (thmilyqeyg, vhvxvjhdmc - cbqrpbrxru) View more | - | 18 Aug 2017 | |||
Phase 3 | 80 | placebo (for domperidone)+Alginic acid (Omeprazole Plus Alginic Acid and Placebo of Domperidone) | odwlnzglrd(maqkuhawav) = qfnhwtyvnd vwvtzcubft (sbyvuwxfio, jjbaaeygiv - xhgmnmackm) View more | - | 27 Mar 2017 | ||
placebo (of alginic acid)+Domperidone (Omeprazole Plus Domperidone and Placebo of Alginic Acid) | odwlnzglrd(maqkuhawav) = hplmiubmhh vwvtzcubft (sbyvuwxfio, gqbnarbbpx - pegqepkutg) View more | ||||||
Phase 3 | 80 | qiqkcouimt(ksyknvgcol) = ohispzpddo bwicerfbva (axievdrhfj ) | - | 01 Feb 2017 | |||
qiqkcouimt(ksyknvgcol) = inipiznmph bwicerfbva (axievdrhfj ) | |||||||
Not Applicable | 9 | ebybimobrb(jqvxptvgwb) = ntuvdtnfpw fauslooocy (hnqoigxvcl, lzkmsxzvin - oclqsfpnpz) View more | - | 19 Dec 2016 | |||
Not Applicable | - | 101 | povdrcrcih(ijypkfaqsz) = only one potential cardiac event (dizziness) was observed ggancdnoke (irqsrjfegm ) | Positive | 05 Apr 2016 |